ACG Group bolsters capsule business with new VP of Europe

ACG, a supplier of integrated manufacturing solutions for pharmaceutical and nutraceutical companies, has appointed Steven Facer as Vice President – Europe.

In his role, he will be responsible for supporting the ambitious growth plans for the company’s capsules business across the region and continue to develop the sales and customer support teams to provide real proximity for European customers.

Mr Facer brings with him more than 25 years of pharmaceutical and healthcare experience spread across global markets. He headed Colorcon as Managing Director EMEA before being appointed as Senior Vice President at Capsugel, where he was the responsible for the EMEA region. He has also served as Vice President at Catalent Pharma.

Mr Facer takes over from Keith Nazareth, who will be retiring following a 27-year career with ACG, where he was responsible for setting up and growing the company’s established European business.

Noronha, CEO of Capsules at ACG, said: “The roles that Steven has previously worked in provide him with operational plant and commercial experience, which gives him a holistic view of the sector and will help us achieve our regional development plans.”

Mr Facer added: “ACG has ambitious growth plans and I am looking forward to undertaking this challenge and being part of this exciting  journey.

“ACG is an exciting brand, with the capsules business already having created a strong foothold in the European market, but there is still a lot of opportunity available and we have some exciting announcements to make in the coming months.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...